Claim Missing Document
Check
Articles

Found 2 Documents
Search

Uji Senyawa Kuersetin dari Ekstrak Bajakah Tampala (Spatholobus littoralis Hassk.) Menggunakan High Performance Liquid Chromatography: Analysis of Quercetin Compound from Extract of Bajakah Tampala (Spatholobus littoralis Hassk.) Using High Performance Liquid Chromatography Munthe, Ervi Audina; Bakring, Abi; Irfan, Ihsanul; Permana, Galih Indra
Jurnal Sains dan Kesehatan Vol. 7 No. 4 (2025): J. Sains Kes.
Publisher : Fakultas Farmasi, Universitas Mulawarman, Samarinda, Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.25026/jsk.v7i4.2492

Abstract

Bajakah tampala (Spatholobus littoralis Hassk) is a plant that grows wild in the forests of Central Kalimantan. Bajakah tampala is a natural resource with potential antioxidant and anti-inflammatory properties. Previous phytochemical research on bajakah tampala stem extract revealed the presence of flavonoid metabolites, alkaloids, tannins, saponins, steroids, triterpenoids, and polyphenols. This study aims to analyze the flavonoid compound quercetin in the ethanol extract of bajakah tampala (Spatholobus littoralis Hassk) using HPLC analysis method. In this study, qualitative and quantitative phytochemical tests were conducted on the 96% ethanol extract of bajakah tampala. The results showed that the 96% ethanol extract of bajakah tampala contains flavonoids and tannins in the qualitative test, while the quantitative test indicated a longer retention time (RT) if the analyte has a higher affinity for the stationary phase, with bajakah tampala showing an RT of 6.639 minutes. The detected quercetin content was 17.54 ppm, indicating a relatively low concentration of quercetin. Keywords:          bajakah tampala, quercetin, flavonoid, tannin   Abstrak Bajakah tampala (Spatholobus littoralis Hassk) merupakan tanaman yang tumbuh liar di hutan Kalimantan Tengah. Bajakah tampala adalah salah satu sumber alam yang berpotensi sebagai antioksidan dan antiinflamasi. Adapun fitokimia penelitian sebelumnya ekstrak batang bajakah tampala mengandung senyawa metabolit flavonoid, alkaloid, tanin, saponin, steroid dan triterpenoid serta polifenol Penelitian ini bertujuan menganalisis senyawa flavonoid kuarsetin dari ekstrak etanol bajakah tampala (Spatholobus littoralis Hassk) menggunakan metode analisis HPLC. Pada penelitian ini dilakukan uji fitokimia kualitatif dan kuantitatif dari ekstrak etanol 96% bajakah tampala. Hasil penelitian menunjukkan bahwa ekstrak etanol 96% bajakah tampala untuk uji kualitatif mengandung flavonoid, tanin dan saponin sedangkan uji kuantitatif menunjukkan waktu retensi (RT) lebih panjang jika analit memiliki afinitas yang lebih tinggi terhadap fase diam pada bajakah tampala dengan RT 6,639 menit dan kadar kuersetin yang terdeteksi adalah 17.54 ppm maka memiliki kadar quersetin yang relatif rendah. Kata Kunci:         bajakah tampala, kuersetin, flavonoid, tanin
Efficacy Of Ertugliflozin Compared With Metformin Or Placebo In Reducing Hba1c Levels Among Adults With Type 2 Diabetes: A Systematic Review And Meta-Analysis Permana, Galih Indra; Munthe, Ervi Audina; Irfan, Ihsanul
Devotion : Journal of Research and Community Service Vol. 6 No. 10 (2025): Devotion: Journal of Community Research
Publisher : Green Publisher Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.59188/devotion.v6i10.25569

Abstract

Type 2 diabetes mellitus (T2DM) remains a global health challenge characterized by chronic hyperglycemia due to insulin resistance and impaired insulin secretion. Glycemic control, measured by glycated hemoglobin (HbA1c), is a crucial indicator of therapeutic effectiveness. This systematic review and meta-analysis aim to compare the efficacy of Ertugliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, with Metformin and Placebo in reducing HbA1c levels among adults with T2DM. Relevant randomized controlled trials (RCTs) published between 2015 and 2025 were identified through PubMed, Scopus, and Cochrane databases. Data extraction and quality assessment followed PRISMA guidelines. The pooled analysis demonstrated that Ertugliflozin significantly reduced HbA1c levels compared to placebo, with mean differences ranging from −0.6% to −1.0% (p < 0.001). When compared to Metformin, Ertugliflozin showed comparable glycemic efficacy, with additional benefits in weight reduction and blood pressure control. Heterogeneity among studies was moderate (I² < 50%), and no severe adverse effects were reported. These findings suggest that Ertugliflozin is an effective and safe alternative or adjunct therapy for adults with T2DM, offering multifaceted metabolic benefits beyond glucose control.